InflaRx (IFRX) Expected to Release Quarterly Earnings on Thursday

InflaRx (NASDAQ:IFRX) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect InflaRx to post earnings of ($0.08) per share and revenue of $0.0060 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.08. On average, analysts expect InflaRx to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

InflaRx Price Performance

IFRX opened at $1.83 on Tuesday. InflaRx has a fifty-two week low of $0.74 and a fifty-two week high of $2.95. The firm has a market capitalization of $132.29 million, a PE ratio of -2.49 and a beta of 2.48. The company’s 50-day moving average is $1.95 and its 200 day moving average is $1.51.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Raymond James Financial raised InflaRx from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $7.00 to $9.00 in a report on Wednesday, May 13th. Zacks Research upgraded InflaRx from a “hold” rating to a “strong-buy” rating in a report on Monday, July 27th. Oppenheimer began coverage on InflaRx in a research report on Friday, April 24th. They issued an “outperform” rating and a $5.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Finally, Guggenheim reaffirmed a “buy” rating and set a $14.00 price objective on shares of InflaRx in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $7.00.

Institutional Investors Weigh In On InflaRx

Several large investors have recently made changes to their positions in IFRX. XTX Topco Ltd bought a new stake in shares of InflaRx during the 4th quarter worth $135,000. Suvretta Capital Management LLC grew its position in InflaRx by 22.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after buying an additional 1,450,000 shares during the period. Quadrature Capital Ltd purchased a new stake in InflaRx during the fourth quarter worth about $104,000. Squarepoint Ops LLC increased its holdings in InflaRx by 72.0% during the fourth quarter. Squarepoint Ops LLC now owns 324,349 shares of the company’s stock worth $328,000 after buying an additional 135,826 shares during the last quarter. Finally, HRT Financial LP bought a new stake in InflaRx in the fourth quarter worth about $47,000. 42.39% of the stock is owned by hedge funds and other institutional investors.

InflaRx Company Profile

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.